



Press release 29 August 2018

Lipum's unique approach for treatment of chronic inflammatory diseases receives 2.2 M€ support from EU

Horizon 2020, the EU framework program for research and development, will grant 2.2 million euros to Lipum's ongoing development of a biological pharmaceutical for treatment of chronic inflammatory diseases.

Lipum has identified the novel target molecule Bile Salt-Stimulated Lipase (BSSL) and preclinical studies have very successfully verified the concept in several well-established models for autoimmune chronic inflammatory diseases, e.g. Rheumatoid Arthritis (RA). A candidate drug, an optimized monoclonal antibody, is now about to be validated and tested including a novel approach to get early Proof of Concept in man. In parallel production of the biological drug will be established for toxicological and clinical study during year 2020. The Horizon 2020 SME Instrument grant will speed up this development work to the benefit of patients, health care and society.

"We are indeed grateful for being selected by EU considering the tough competition. There is a significant unmet need for the treatment of these diseases and we have first-in-class potential", says CEO Einar Pontén.

Lipum initially intends to address Juvenile Idiopathic Arthritis (JIA) that affects children. Since this is a rare disease there is potential to obtain an orphan drug designation (ODD) for faster time to market.

"We presented an innovative way to get clinical proof of concept faster. I think that also contributed to our success in being selected for the grant", Pontén continues.

Contact details

Einar Pontén, CEO

Mail: einar.ponten@lipum.se

Mobile: +46 70-5783495

Web: www.lipum.se

About Lipum AB

Lipum is a biopharmaceutical company focused on chronic inflammation and autoimmune diseases. The company has identified a unique protein as a cause and is therefore developing new biological drugs for blocking the protein as treatment.